Triamterene

CHEMBL585 Phase 4 승인됨 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

253.3 g/mol

LogP

1.0

Phase

4

Potassium-sparing action separates triamterene from the loop and thiazide diuretics, which promote potassium loss along with sodium and water. The drug increases renal excretion of excess fluid in oedema arising from heart failure, hepatic disease or renal disease while retaining potassium, and it is frequently combined with a potassium-wasting diuretic so that the two effects offset one another. The corresponding hazard is hyperkalaemia, and both serum potassium and renal function are monitored during treatment for that reason. The compound is a small molecule with the formula C12H11N7 and a molecular weight near 253.3 g/mol. It is approved and has completed the final phase of clinical development.

This potassium-sparing diuretic helps the kidneys remove excess fluid from the body without causing the loss of potassium, and is used to treat fluid retention (edema) related to heart failure, liver disease, or kidney disease, often in combination with another diuretic. Unlike most diuretics that cause potassium loss, triamterene helps retain potassium, so potassium supplements or potassium-rich foods should be avoided. Kidney function and potassium levels need regular monitoring.

분자량

253.2600 g/mol

LogP

1.00

TPSA

130.00 Å²

리핀스키 5의 법칙

통과

치료 영역

Hepatology Nephrology Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure

Embed this structure

SMILES

Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1

InChI

InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)

Molecular Formula

C12H11N7

HBD / HBA

3 / 7

회전 가능 결합

1

무거운 원자

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This potassium-sparing diuretic helps the kidneys remove excess fluid from the body without causing the loss of potassium, and is used to treat fluid retention (edema) related to heart failure, liver disease, or kidney disease, often in combination with another diuretic. Unlike most diuretics that cause potassium loss, triamterene helps retain potassium, so potassium supplements or potassium-rich foods should be avoided. Kidney function and potassium levels need regular monitoring.

Yes, Triamterene is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL585. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5546. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Triamterene PillFYI에서

구조

핵심 데이터

분자식: C12H11N7
동의어: 3

외부 링크

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.